
Tech • AI • Robotics • Game
A new AI protein-design system, RFD4-Proteina, is reported to create drug candidates and industrial enzymes far faster and with much stronger performance than previous computational methods.
Proteins perform many of biology’s core functions, from digesting food and powering motion to controlling electrical signaling in the brain. Designing new proteins could extend those natural capabilities to human problems that evolution never encountered, including breaking down synthetic pesticides, targeting new cancer markers, tackling Alzheimer’s disease, and improving nitrogen fixation.
The project began about a year ago with a small team from NVIDIA Research and the Baker Lab at the University of Washington. The collaboration combined protein-design expertise with algorithm and systems optimization, aiming to produce a model that could outperform earlier generations of computational design tools.
RFD4-Proteina combines ideas from the RFdiffusion family of models with concepts from Proteina Complexa, a model series developed at NVIDIA. Researchers describe the merged system as more powerful than previous approaches for designing proteins that bind to chosen molecular targets.
In therapeutic development, moving from an early concept to an injectable medicine often takes 10 to 12 years and around $1 billion. Researchers say the new system can generate molecules directly from computation that bind intended targets immediately, potentially compressing part of the discovery timeline.
Tests reported with RFD4-Proteina showed designed molecules binding their targets with a 10-fold to 1,000-fold increase in tightness compared with earlier designs. Stronger binding is a key metric in drug discovery because it can indicate a better chance of effective targeting and lower required doses.
One research focus involved engineering enzymes to break down man-made pesticides. Enzymes are valued because they can perform highly selective chemistry, offering a cleaner alternative for environmental remediation than many conventional chemical processes.
In that pesticide-enzyme project, work that had taken roughly a year using previous methods was repeated in just four days with RFdiffusion4-Proteina. The top enzyme produced by the new model was reported to be more than 1,000 times better than earlier versions developed over the previous year.
The reported gains from RFD4-Proteina suggest AI-designed proteins may significantly accelerate both drug discovery and environmental biotechnology. If those results hold broadly, protein engineering could become faster, cheaper and more effective across multiple industries.
Ask a question